Health care workers received the first shots in Taiwan's COVID-19 vaccination drive Monday, beginning a campaign that won't use supplies from China amid uneven distribution of the vaccines globally.
Taiwan has on hand 117,000 doses of the AstraZeneca vaccine, which it is distributing to healthcare workers across 57 hospitals.
Taiwanese premier Su Tseng-chang launched the drive by receiving the first shot at National Taiwan University Hospital in the capital Taipei. After 30 minutes of rest, there's no signs of any discomfort, he said.
The rest period is for monitoring recipients for any adverse reactions.
Last week, more than a dozen nations suspended use of the AstraZeneca vaccine after a few dozen people among the millions who've received the vaccine developed blood clots.
The European Union's drug regulatory agency concluded after a review it couldn't rule out a direct link but the benefits of using the vaccine outweigh the possible risks.
Taiwan has signed contracts securing 10 million doses of the AstraZeneca vaccine, 5.05 million doses of the Moderna vaccine, and 4.76 million doses of vaccines through COVAX.
The island is planning to administer its full initial supply to 117,000 individuals to ensure the broadest protection. The first dose provides an efficacy rate of 71 per cent and the second dose meant to be given eight weeks later boosts its effectiveness to 81 per cent, authorities have said previously.
Taiwan has yet to announce a vaccination campaign for the public.
Countries around the world are scrambling for vaccines, which have been distributed unevenly with rich countries buying up a majority of the doses. China has stepped in to offer hundreds of millions of doses of its own vaccines across the developing world, but Taiwan has refrained from buying them.
Taiwanese law bans import of Chinese vaccines made for human use. The island's health minister had said in February there were no considerations to amending the law and no experts have made a special recommendation for Chinese vaccines.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)